AI & Machine Learning

Instinct Science says its Attending tool answers clinical questions using peer-reviewed veterinary content, with safety-critical dosing drawn directly from Plumb's.

All 16 TG4050-treated HNSCC patients remained relapse-free at 41 months' median follow-up, with full Phase 1 data now published in Nature Communications.

Discovery Health reports female members complete 1.5 times more preventive health actions than male members on its AI-powered Personal Health Pathways platform.

The NYSE-listed musculoskeletal device maker is buying Durham-based Higgs Boson Health to build out a surgical intelligence and patient-journey platform.

The Hong Kong-listed platform reported RMB 1.82bn in H1 2026 revenue, driven by its proprietary XingShi LLM and a fast-growing chronic disease

BridgeBio's Attruby generated CMR evidence of cardiac structural reversal and 65 extra days alive out of hospital at three years in ATTR-CM patients.

The capsule endoscopy company reported Q2 2026 revenue of $3.6m and expects US clearance of its AI-assisted reading tool by end of Q3.

Independent Dutch government-funded FUSION trial found adding Heartflow's AI analysis to standard CT scans halved avoidable invasive coronary procedures at one year.

Trimedx says new natural-language AI capabilities in TMX Protect cut medical device cybersecurity remediation time by 75% on average.

Philips will work with Johns Hopkins and Boston University to develop remote and automated endovascular stroke procedures under the ARPA-H AIR programme.

Big Digital Energy's joint venture has signed a non-binding letter of intent with Tensor IQ to develop a 17 MW AI and HPC

A 350-patient prospective study found the handheld 6-lead ECG device detected arrhythmias in 14.9% of patients versus 7.7% for standard ambulatory

Imamu Tomlinson, CEO of the $2.6bn physician-owned partnership, argues burnout is a systemic failure, not an individual one.

Tracxn data shows five companies absorbed 84% of capital raised, with London capturing 98% of the national total.

Deep Origin's physics-augmented virtual screening framework achieved a 30.6% hit rate on CD73, against a 0.3% baseline from a prior AI

The French medtech firm will use the growth loan to commercialise TAVIpilot, its FDA-cleared AI-guided software for transcatheter aortic valve procedures.

The MIT spinout will use five-year federal funding to develop a magnetic robotic navigation platform for autonomous endovascular thrombectomy.

Median Technologies' Eyonis will distribute its FDA-cleared eyonis LCS tool through Canon Medical subsidiary Olea Medical across the US and Europe.

Lōkahi Therapeutics takes control of Nasdaq-listed Glucotrack, forming a public platform to acquire and advance healthcare assets via an AI-driven model.